Back to News
Market Impact: 0.12
Avacta Appoints Blom To Board As Audit Committee Chair; Advances Pre|CISION Platform
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Avacta Group appointed Mats Blom as a non-executive director and Chair of its Audit Committee. The clinical-stage oncology company said Blom will join the board as it develops its pre|CISION tumor-activated drug-delivery platform; no financial, clinical-trial, or operating updates were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
AVCT0.20
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- FG Nexus repurchases 46% of outstanding common shares
- Indonesian Power Politics, Not Markets, Forced Out Finance Chief
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check